A psychiatric perspective on the therapy of psychosis in systemic lupus erythematosus

Lupus

Volumn 12, Issue 12, 2003, Pages 947-949

  Bodani, M ^a   Kopelman, M D ^a  

^a ST THOMAS HOSPITAL   (United Kingdom)

Author keywords

Cyclophosphamide; Lupus; Neuropsychiatric; Psychosis

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; CYCLOPHOSPHAMIDE; HALOPERIDOL; METHYLPREDNISOLONE; OLANZAPINE; QUETIAPINE; RISPERIDONE; SULPIRIDE;

CYSTITIS; DISEASE SEVERITY; HERPES ZOSTER; HUMAN; NEUROPSYCHIATRY; OVARY INSUFFICIENCY; PATHOPHYSIOLOGY; PREVALENCE; PRIORITY JOURNAL; PSYCHOSIS; REVIEW; SIDE EFFECT; SYSTEMIC LUPUS ERYTHEMATOSUS;

ADULT; AGE DISTRIBUTION; AGED; ANTIPSYCHOTIC AGENTS; COMORBIDITY; CYCLOPHOSPHAMIDE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; LUPUS VASCULITIS, CENTRAL NERVOUS SYSTEM; MALE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; PREVALENCE; PROGNOSIS; PSYCHOTIC DISORDERS; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; SEX DISTRIBUTION; TREATMENT OUTCOME;

EID: 0347123628     PISSN: 09612033     EISSN: None     Source Type: Journal    
DOI: 10.1191/0961203303lu507oa     Document Type: Review

References (19)

1. American Psychiatric Association. Diagnostic and statistical manual of mental disorders, fourth edition. Virginia: American Psychiatric Association, 1994.
2. World Health Organization. The ICD-10 Classification of Mental and Behavioural Disorders. WHO, 1992.
3. Tan EM, Cohen AS, Fries JF et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25: 1271-1277.
4. ACR Ad Hoc Committee on Neuropsychiatric Lupus Nomenclature. Arthritis Rheum 1999; 4: 599-608.
5. Brey RL, Holliday SL, Saklad AR et al. Neuropsychiatric syndromes in lupus: prevalence using standardized definitiion. Neurology 2002; 58: 1214-1220.
6. Ainiala H, Loukkola J, Peltola J et al. The prevalence of neuropsychiatric syndromes in systemic lupus erythematosus. Neurology 2001; 57: 496-500.
7. Mok CC, Lau CS, Wong RWS. Neuropsychiatric manifestations and their clinical associations in Southern Chinese patients with systemic lupus erythematosus. J Rheumatol 2001; 28: 766-771.
8. West SG. Lupus and the Central Nervous system. Curr Opin Rheum 1996; 8: 408-414.
9. Bruyn GAW. Controversies in lupus: nervous system involvement. Annals Rheum Dis 1995; 54: 159-167.
10. McLean BN. Neurological involvement in systemic lupus erythematosus. Curr Opin Neurology 1998; 11: 247-151.
11. Sabbadini MG, Manfredi AA, Bozzolo E et al. Central nervous system involvement in systemic lupus erythematosus patients without overt neuropsychiatric manifestations. Lupus 199; 8: 11-19.
12. Hermosillo-Romo D, Brey RL. Diagnosis and management of patients with neuropsychiatric lupus erythematosus (NPSLE). Best Prac Res Clin Rheumatol 2002; 16: 229-244.
13. Khoshbin S, Glanz BI, Schur PH. Neuropsychiatric syndromes in systemic lupus erythematosus: a new look. Clin Exp Rheumatol 1999; 17: 395-398.
14. Schroeder JO, Euler HH. Recognition and management of systemic lupus erythematosus. Drugs 1997; 54: 422-434.
15. Neuwelt CM, Lacks S, Kaye BR et al. Role of intravenous cyclophosphamide in the treatment of severe neuropsychiatric systemic lupus erythematosus. Am J Med 1995; 98: 32-41.
16. Boumpas DT, Yamada H, Patronas NJ et al. Pulse cyclophosphamide for severe neuropsychiatric lupus. Q J Med 1991; 81: 975-984.
17. Ramos PC, Mendez MJ, Ames PR, Khamashta MA, Hughes GR. Pulse cyclophosphamide in the treatment of neuropsychiatric systemic lupus erythematosus. Clin Exp Rheumatol 1996; 14: 259-299.
18. Takada K, Illei GG, Boumpas DT. Cyclophosphamide for the treatment of systemic lupus erythematosus. Lupus 2001; 10: 154-161.
19. Baca V, Lavalle C, Garcia R et al. Favourable response to intravenous methylprednisolone and cyclophosphamide in children with severe neuropsychiatric lupus. J Rheumatol 1999; 26: 432-439.